MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022
April 20, 2022 16:05 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 15, 2022 09:00 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., April 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...
MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue
April 12, 2022 16:05 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., April 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Reports Fourth Quarter and Full Year Financial Results
March 22, 2022 16:05 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., March 22, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer
March 09, 2022 16:15 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...
MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022
February 24, 2022 08:00 ET
|
MaxCyte, Inc
GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...
MaxCyte to Participate in Upcoming Investor Conferences
February 14, 2022 08:00 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 11, 2022 17:00 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
February 01, 2022 02:00 ET
|
MaxCyte, Inc
NEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering,...
MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results
January 24, 2022 02:30 ET
|
MaxCyte, Inc
Fourth quarter 2021 revenue expected to be greater than $10 million Full year 2021 revenue expected to be greater than $33.7 millionInstalled base of greater than 500 instruments 15 SPLs, covering...